March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
Hindistanda CAR T Cell terapiyası müalicəsinin arxasındakı elmi kəşf edin! Bu inqilabi müalicənin immun hüceyrələrinizi xərçənglə mübarizə aparanlara necə çevirdiyini araşdırın. Bu möcüzəvi terapiya və necə .. haqqında daha çox öyrənmək üçün indi blogumuzu oxuyun.
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..
May 2023: Əvvəllər müalicə almamış və Beynəlxalq Proqnostik İndeksi olan yüksək dərəcəli B hüceyrəli lenfoması (HGBL), başqa cür təyin olunmamış (NOS) və ya diffuz böyük B hüceyrəli lenfoması (DLBCL) olan yetkin xəstələr üçün.
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
Noyabr 2022: Doksorubisin, vinkristin, etoposid, prednizon və siklofosfamidin brentuksimab vedotin (Adcetris, Seagen, Inc.) ilə kombinasiyası Qida və Dərman İdarəsi tərəfindən uşaqlarda istifadə üçün təsdiq edilmişdir.